FAIRFIELD, N.J.--(BUSINESS WIRE)--Unigene Laboratories, Inc. (OTCBB: UGNE) reported that the US Food and Drug Administration (FDA) approved a modification for a key enzyme, the first of two proposed improvements for its patented manufacturing process for calcitonin, the active ingredient in Fortical®, Unigene’s nasal spray product for the treatment of osteoporosis. The FDA is still reviewing a second improvement to the production process that, if approved, is expected to improve batch yields of the product by a factor of three.
